论文部分内容阅读
本文比较了再次TUR后与初次TUR术后进行丝裂霉素(MMC)灌注对T1膀胱癌复发、进展和总体生存率的影响。将2001年1月至2005年1月新诊断的148例T1膀胱肿瘤中的142例随机分2组。组1(74例)行再次TUR手术,随后进行膀胱内MMC灌注化疗;组2(68例)于初次TUR术后行膀胱内MMC灌注化疗。再次TUR术于初次TUR术后2～6周完成。排除手术切除不彻底、伴原位癌及肌层浸润的病例。
This article compared the effect of mitomycin (MMC) infusion on the recurrence, progression and overall survival of T1 bladder cancer after TUR and TUR. A total of 142 newly diagnosed T1 bladder tumors from January 2001 to January 2005 were randomly divided into two groups. Group 1 (74 cases) underwent TUR surgery again, followed by MMC intravesical chemotherapy; group 2 (68 cases) underwent intravesical MMC infusion chemotherapy after initial TUR. TUR again in the first TUR surgery after 2 to 6 weeks to complete. Exclude the surgical excision is not complete, with carcinoma in situ and myometrial infiltration of cases.